Vanda Pharmaceuticals | VNDA - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Akebia Therapeutics USD -5.45M 9.4M 2025-12
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Anika Therapeutics USD 646K 3.88M 2025-12
Arrowhead Research USD 40.81M 3.3M 2025-12
AstraZeneca USD 7.11B 4.14B 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Insmed USD -249.71M 11.64M 2025-12
J&J USD 6.62B 1.03B 2026-03
Lexicon Pharmaceuticals USD -14.78M 2.59M 2025-12
Ligand Pharmaceuticals USD 158.89M 149.17M 2025-09
Merck USD -1.88B 8.12B 2026-03
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Moderna USD -1.39B 531M 2026-03
Novartis USD 4.06B 521M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.94B 239M 2026-03
Takeda JPY 168.82B 479.89B 2025-12
Teva Pharmaceutical Industries USD 758M 271M 2026-03
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12
Veracyte USD 24.63M 1.52M 2025-12